Curi RMB Capital LLC Invests $903,000 in Vaxcyte, Inc. (NASDAQ:PCVX)

Curi RMB Capital LLC purchased a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 7,901 shares of the company's stock, valued at approximately $903,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Riverview Trust Co bought a new stake in Vaxcyte during the 3rd quarter valued at $27,000. Fifth Third Bancorp bought a new stake in shares of Vaxcyte during the second quarter valued at about $35,000. Blue Trust Inc. lifted its holdings in Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company's stock worth $42,000 after purchasing an additional 93 shares during the period. J.Safra Asset Management Corp grew its position in Vaxcyte by 649.4% in the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company's stock valued at $46,000 after buying an additional 526 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in Vaxcyte during the 2nd quarter valued at about $70,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Jefferies Financial Group lifted their price target on Vaxcyte from $108.00 to $129.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, November 6th. BTIG Research lifted their target price on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, September 3rd. Finally, Bank of America boosted their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $147.50.

Insider Activity

In related news, CFO Andrew Guggenhime sold 42,000 shares of Vaxcyte stock in a transaction on Friday, October 18th. The stock was sold at an average price of $115.39, for a total transaction of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares of the company's stock, valued at approximately $10,429,294.37. This trade represents a 31.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $37,822,574.24. The trade was a 3.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,464 shares of company stock worth $12,640,276. 3.10% of the stock is owned by corporate insiders.

Vaxcyte Stock Down 6.3 %

Shares of NASDAQ PCVX traded down $5.85 during mid-day trading on Friday, hitting $86.83. 4,629,278 shares of the company traded hands, compared to its average volume of 885,972. Vaxcyte, Inc. has a 1 year low of $48.24 and a 1 year high of $121.06. The stock has a market capitalization of $10.82 billion, a price-to-earnings ratio of -18.88 and a beta of 1.01. The business has a 50 day moving average of $110.67 and a two-hundred day moving average of $88.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the company posted ($0.91) earnings per share. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.